US 11,896,712 B2
Method for treating a metabolite toxicopathy
Jean-Christophe Leroux, Zurich (CH); and Vincent Forster, Zurich (CH)
Assigned to Versantis AG, Zurich (CH)
Filed by Versantis AG, Zurich (CH)
Filed on Sep. 11, 2020, as Appl. No. 17/018,438.
Application 17/018,438 is a division of application No. 16/165,202, filed on Oct. 19, 2018, abandoned.
Application 16/165,202 is a division of application No. 14/420,654, granted, now 10,596,114, issued on Mar. 24, 2020, previously published as PCT/EP2013/002352, filed on Aug. 6, 2013.
Claims priority of application No. 12005796 (EP), filed on Aug. 9, 2012.
Prior Publication US 2021/0128470 A1, May 6, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/127 (2006.01); A61M 1/28 (2006.01)
CPC A61K 9/127 (2013.01) [A61K 9/1271 (2013.01); A61M 1/287 (2013.01); A61K 9/1272 (2013.01); A61K 9/1273 (2013.01)] 32 Claims
OG exemplary drawing
 
1. A method for treating a metabolite toxicopathy in a patient in need thereof, comprising:
the step of administering a therapeutically effective amount of a liposome composition into the peritoneal cavity of said patient, wherein the pH within the liposomes differs from the pH in the peritoneal cavity, wherein the pH within the liposomes results in liposomes-encapsulated charged metabolite, wherein the metabolite toxicopathy is selected from the group consisting of hyperammonemia, argininosuccinic acidemia, hyperuricemia, isovaleric acidemia and propionic acidemia, and wherein the liposome composition comprises liposomes having a diameter size larger than 600 nm; and
the step of extracting the liposomes-encapsulated charged metabolite from the peritoneal cavity.